Data on interferon-alpha (IFNα) efficacy in MPN patients further supports the theory of immune suppression: IFNα is an immunostimulatory drug capable of inducing long-lasting hematological and molecular remission in these patients (17, 18). Here, IFNA1 is linked to myeloproliferative disorder.